Biomarker testing is changing how colorectal cancer is treated, giving patients more personalized and effective care. By analyzing the genetic and molecular features of

It’s good news in the fight against colorectal cancer: A new test can detect the disease with a simple blood draw. But don’t cancel your colonoscopy just yet — that old standby is still more reliable and effective than newer screening methods.

NEW YORK, Oct. 28 (UPI) --New blood tests screen for colorectal cancer in a much less invasive way than colonoscopy, but deaths will increase if many people choose this alternative, a new study indicates. The study was published Monday in Annals of ...

Saga Diagnostics expanded the use of its ultrasensitive blood test to include detection of tiny amounts of colorectal cancer that may remain in the body after treatment and can signal a higher risk of recurrence.

A new blood test to screen for colon cancer was approved Monday by the Food and Drug Administration (FDA), aimed at finding cancer when it’s still in the early stage and treatable. The blood test, known as Shield and manufactured by Guardant Health, has ...

A second blood test shows promise for the detection of colon cancer, according to a new study. The first, called Shield, was approved by the Food and Drug Administration in July for people 45 and older who are at average risk for colorectal cancer.

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication in npj Precision Oncology of the validation study for its Latitude tissue-free molecular residual disease assay (tfMRD) in colorectal cancer (CRC).

A blood-based colorectal cancer (CRC) screening test, SimpleScreen™, has shown a significant leap in performance, demonstrating high sensitivity for both malignant and advanced precancerous lesions (APL). 1 Data from a large-scale validation study will be presented at the ASCO Gastrointestinal Cancers Symposium.